BOLD
Boundless Bio, Inc. NASDAQ Listed Jul 20, 2016$1.55
Mkt Cap $34.7M
52w Low $0.96
77.1% of range
52w High $1.73
50d MA $1.28
200d MA $1.22
P/E (TTM)
-0.6x
EV/EBITDA
-0.9x
P/B
0.4x
Debt/Equity
0.5x
ROE
-59.0%
P/FCF
-0.6x
RSI (14)
—
ATR (14)
—
Beta
-0.26
50d MA
$1.28
200d MA
$1.22
Avg Volume
223.7K
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
9880 Campus Point Drive · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | AMC | -0.44 | -0.58 | -31.8% | 1.14 | +1.8% | +0.9% | +0.9% | -3.4% | -0.9% | +0.9% | — |
| Nov 5, 2025 | AMC | -0.53 | -0.62 | -17.0% | 1.26 | +3.2% | +0.0% | -2.4% | -1.6% | +4.1% | -2.4% | — |
| Aug 5, 2025 | AMC | -0.75 | -0.70 | +6.7% | 1.18 | -0.8% | +0.0% | -3.4% | -5.3% | +2.8% | +0.9% | — |
| May 9, 2025 | AMC | -0.68 | -0.71 | -4.4% | 1.44 | +4.2% | +3.5% | +4.0% | -3.9% | +13.4% | -2.4% | — |
| Mar 27, 2025 | AMC | -0.74 | -0.74 | +0.0% | 1.51 | -1.3% | -0.7% | +0.7% | -4.0% | +2.8% | -7.4% | — |
| Nov 7, 2024 | AMC | -0.76 | -0.74 | +2.6% | 3.32 | +2.4% | +5.4% | +2.3% | +3.4% | -3.5% | -9.2% | — |
| Aug 12, 2024 | AMC | -0.78 | -0.77 | +1.3% | 2.88 | +2.4% | +2.8% | +0.7% | +12.1% | -0.9% | +7.6% | — |
| May 13, 2024 | AMC | -0.55 | -12.27 | -2130.9% | 9.52 | -3.7% | -2.5% | +2.7% | +4.5% | -2.9% | +9.8% | — |
| Dec 31, 2023 | AMC | — | -0.55 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.59 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -0.56 | — | — | — | — | — | — | — | — | — |
| Mar 30, 2023 | AMC | — | -0.53 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.08 | $1.10 | +1.9% | +2.8% | +0.9% | +4.5% | +0.0% | -0.9% |
| May 28 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $1.30 | $1.34 | +3.1% | -7.7% | -2.5% | -6.0% | +2.7% | -0.9% |
| Dec 13 | Guggenheim | Downgrade | Buy → Neutral | — | $2.95 | $2.84 | -3.7% | -16.6% | +2.0% | +0.8% | -1.2% | +0.8% |
| Dec 8 | Evercore ISI | Downgrade | Outperform → In Line | — | — | — | — | — | — | — | — | — |
| Dec 5 | JP Morgan | Downgrade | Overweight → Neutral | — | — | — | — | — | — | — | — | — |
| Dec 4 | SVB Leerink | Downgrade | Outperform → Perform | — | — | — | — | — | — | — | — | — |
| Dec 3 | SVB Leerink | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Dec 3 | BMO Capital | Downgrade | Outperform → Perform | — | — | — | — | — | — | — | — | — |
| Dec 3 | Raymond James | Downgrade | Outperform → Perform | — | — | — | — | — | — | — | — | — |
| Dec 3 | Chardan Capital | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Dec 2 | Guggenheim | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Dec 2 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Dec 2 | Citigroup | Upgrade | Sell → Neutral | — | — | — | — | — | — | — | — | — |
| Dec 2 | Piper Jaffray | Downgrade | Overweight → Neutral | — | — | — | — | — | — | — | — | — |
| Dec 2 | Raymond James | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Dec 2 | BMO Capital | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Dec 2 | Baird | Upgrade | Underperform → Neutral | — | — | — | — | — | — | — | — | — |
| Dec 2 | Wedbush | Downgrade | Outperform → Neutral | — | — | — | — | — | — | — | — | — |
| Nov 18 | Evercore ISI | Upgrade | In Line → Outperform | — | — | — | — | — | — | — | — | — |
| Oct 3 | Baird | Maintains | Underperform → Underperform | — | — | — | — | — | — | — | — | — |
| Sep 2 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Apr 16 | SVB Leerink | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Feb 24 | Chardan Capital | Upgrade | Neutral → Buy | — | — | — | — | — | — | — | — | — |
| Jan 10 | Guggenheim | Upgrade | Neutral → Buy | — | — | — | — | — | — | — | — | — |
| Dec 9 | Citigroup | Maintains | Neutral → Neutral | — | — | — | — | — | — | — | — | — |
| Nov 26 | JP Morgan | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Nov 7 | William Blair | Downgrade | Outperform → Perform | — | — | — | — | — | — | — | — | — |
| Nov 6 | William Blair | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Sep 7 | B. Riley FBR | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Aug 21 | Citigroup | Maintains | Neutral → Neutral | — | — | — | — | — | — | — | — | — |
| Aug 7 | Mizuho | Upgrade | Neutral → Buy | — | — | — | — | — | — | — | — | — |
| Jun 26 | Chardan Capital | Maintains | Neutral → Neutral | — | — | — | — | — | — | — | — | — |
| Feb 13 | Mizuho | Maintains | Neutral → Neutral | — | — | — | — | — | — | — | — | — |
| Dec 20 | H.C. Wainwright | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Dec 5 | BMO Capital | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Oct 17 | William Blair | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Oct 15 | Evercore ISI | Downgrade | Outperform → In Line | — | — | — | — | — | — | — | — | — |
| Oct 12 | Raymond James | Maintains | Market Perform → Perform | — | — | — | — | — | — | — | — | — |
| Sep 21 | Bank of America | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 17 | Evercore ISI | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Aug 15 | Wedbush | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Aug 15 | PiperJaffray | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Aug 15 | Cowen & Co. | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
No insider trades available.
8-K · 2.02
!! High
Boundless Bio, Inc. -- 8-K 2.02: Earnings Results
Boundless Bio (BOLD) reported earnings results, with detailed financial performance metrics available in the attached press release.
May 8
8-K · 1.02
!! High
Unknown — 8-K 1.02: Material Agreement Terminated
BOLD terminated a material agreement, which could reduce revenue, partnerships, or operational capabilities, warranting immediate investigation into the agreement's importance and replacement plans.
Apr 13
8-K · 5.02
!!! Very High
Boundless Bio, Inc. -- 8-K 5.02: Executive Change
Boundless Bio (BOLD) lost board member Christine Brennan effective March 3, 2026, potentially signaling internal governance shifts that investors should monitor for strategic implications.
Mar 9
Data updated apr 24, 2026 10:28pm
· Source: massive.com